Biogen upgraded to Buy from Neutral at UBS
January 31, 2018 at 08:42 AM EST
UBS analyst Carter Gould upgraded Biogen to Buy and raised his price target for the shares to $410 from $318.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|